Elastrin Therapeutics: Funding, Investors & Team (Sep 2026)
Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work. The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.
Elastrin Therapeutics has raised $14.8M across 2 funding rounds on record, the most recent an undisclosed round of $4.8M announced in Nov 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Elastrin Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2023.
Elastrin Therapeutics Funding Rounds
Elastrin Therapeutics raised $10.0M in an undisclosed round announced in Apr 2022.
1.6 years later, an undisclosed round of $4.8M was announced in Nov 2023.
Elastrin Therapeutics Founders and Leadership Team
Contact details for the Elastrin Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Elastrin Therapeutics Funding Compared to Other Biotechnology Startups
Elastrin Therapeutics' latest round of $4.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Elastrin Therapeutics in Biotechnology and Simpsonville
Companies Similar to Elastrin Therapeutics
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
Elastrin Therapeutics Funding FAQs
What does Elastrin Therapeutics do?
Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work. The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.
How much funding has Elastrin Therapeutics raised?
Elastrin Therapeutics has raised $14.8M across 2 rounds on record. The most recent is an undisclosed round of $4.8M announced in Nov 2023.
When did Elastrin Therapeutics last raise funding?
Elastrin Therapeutics' most recent funding round on record is an undisclosed round of $4.8M, announced in Nov 2023.
Who founded Elastrin Therapeutics?
FundedIQ lists Douglas Mulhall (Founder) at Elastrin Therapeutics.
Who is the CEO of Elastrin Therapeutics?
Matthias Breugelmans is listed as CEO at Elastrin Therapeutics.
Where is Elastrin Therapeutics headquartered?
Elastrin Therapeutics is based in Simpsonville, South Carolina, United States.
How many employees does Elastrin Therapeutics have?
Elastrin Therapeutics is in the 1-10 employee band.
How does Elastrin Therapeutics' funding compare to other Biotechnology startups?
Elastrin Therapeutics' latest round of $4.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Elastrin Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Elastrin Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.